Healthcare & Water Technologies generated strong mid-single-digit organic growth driven by medical packaging and industrial water demand, while CEO Lori Koch praised the company's disciplined execution despite macro headwinds. DuPont is reshaping its portfolio through a $1.2 billion aramids business sale and $2 billion share buyback, with shares surging 50.48% over the past 12 months.
Cyborg Score Rationale
Q4 2025 reported solid earnings with adjusted EPS exceeding estimates and 3% organic sales growth anticipated for 2026. Operating EBITDA margins expanded 80 basis points to 24.2%, demonstrating operational leverage. Strategic portfolio streamlining and innovation-driven growth support favorable long-term positioning.
Top Insights
New products represented over $2 billion in sales with a 30% vitality index, demonstrating innovation's impact on margin and revenue growth.
Healthcare & Water segment grew 3% organically while Diversified Industrials declined 4% from construction weakness, showing segment divergence.
Expected closing of $1.2 billion aramids business sale by end of Q1 2026 continues aggressive portfolio optimization.
Analyst consensus is "Buy" with 12-month price target of $61.46, representing 22.95% upside from recent pricing.
Named Competitors
LyondellBasell — Specialty chemicals and polymers producer
Air Products — Industrial gases and specialty chemicals
Ecolab — Water treatment and industrial sanitation
PPG Industries — Specialty coatings and materials
Recent Developments
(February 2026) FilmTec Fortilife XC160UHP reverse osmosis elements for industrial wastewater treatment announced as award winner.
(February 2026) Q4 2025 earnings released February 10, 2026, revealing solid performance and 2026 guidance modestly ahead of consensus.
(January 2026) DuPont announced appointment of D.G. to leadership position.
Open the full interactive DuPont de Nemours, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.